Specific preadaptations of Rhodococcus equi cooperate with its Virulence-associated protein A during macrophage

Thomas Haubenthal1, Philipp Hansen1, Ina Krämer1

  • 1Institute for Cell Biology, University of Bonn, Bonn, Germany.

Molecular Microbiology
|January 11, 2023
PubMed

Insights

Rhodococcus equi uses Virulence-associated protein A (VapA) to survive inside macrophages, but this protein is thermosensitive in related species. Understanding VapA

Area of Science:

  • Microbiology
  • Immunology
  • Pathogenesis

Background:

  • Rhodococcus equi (Prescotella equi) is a Gram-positive lung pathogen affecting foals and immunocompromised humans.
  • Intra-macrophage growth of R. equi depends on Virulence-associated protein A (VapA), which neutralizes phagosomal pH.

Purpose of the Study:

  • To investigate the specificity of VapA's function in supporting intra-macrophage bacterial growth.
  • To explore the role of temperature and host defenses in R. equi pathogenesis.
  • To understand the implications of VapA's role in vaccine development.

Main Methods:

  • In vitro growth experiments with various bacterial species and isolated macrophage lysosomes.
  • Modified infection schemes to assess bacterial survival and multiplication under different conditions.
  • Analysis of VapA production and secretion by R. equi during host-pathogen interaction.

Main Results:

  • VapA specifically supports R. equi intra-macrophage growth; other bacteria do not benefit.
  • Rhodococcus defluvii, a related species, fails to multiply at 37°C due to VapA thermosensitivity, but grows at lower temperatures, demonstrating 'thermal restriction'.
  • R. equi survives low pH in lysosomes for hours, producing VapA to neutralize the environment and grow.

Conclusions:

  • VapA is a key virulence factor for R. equi, enabling survival and multiplication within macrophages.
  • Thermosensitivity of VapA in related species and 'thermal restriction' offer insights into host-pathogen specificity.
  • R. equi may initially encounter the host without VapA, suggesting novel vaccine targets.